- €50.59bn
- €45.99bn
- $4.15bn
Brief: Argenx Q4 Net Income USD 532.95 Million
Brief: Argenx: Positive Topline Results From Phase 3 Adapt Oculus Trial Of Vyvgart In oMG
Argenx shares climb as FDA reviews Vyvgart additional application
Brief: Argenx: FDA Accepts Priority Review sBLA for Vyvgart in Seronegative gMG
Brief: Argenx Preliminary FY Global Product Net Sales $4.15 Bln
Europe-US relisting trend: $1 trln more in store
Brief: Karen Massey To Become CEO Of Argenx
Argenx seen down after halt to eye disease studies for efgartigimod
Brief: Argenx: UplighTED Studies Of Efgartigimod SC In Thyroid Eye Disease To Be Discontinued
Europe Research Roundup: Auto1 Group, Roche Holding, Sanofi
Brief: ArgenX Announces Results Of Extraordinary General Meeting Of Shareholders
U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx SE, Cardinal Health Inc
Europe Research Roundup: Avolta, Puma, Renk Group
Brief: Argenx SE Q3 NET INCOME USD 344.258 MILLION
Refile: BUZZ-'Overall a relief': TrumpRx price cuts deals boost European pharma stocks
Top of the Street: Telenor, Telia, Novartis, Argenx, Puma
Deutsche Bank cuts Argenx to 'hold' on valuation
Europe Research Roundup: Energean, Playtech, Vistry Group
Europe Research Roundup: Alfen, Argenx, JDE Peet's